Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
  • Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Thumbnail
View/Open
Accepted version (221.9Kb)
Supporting information (459.2Kb)
Supporting information (416.8Kb)
Supporting information (17.49Kb)
Date
2018-06
ICR Author
Swerdlow, Anthony
Schoemaker, Minouk
Author
Ge, W
Clendenen, TV
Afanasyeva, Y
Koenig, KL
Agnoli, C
Brinton, LA
Dorgan, JF
Eliassen, AH
Falk, RT
Hallmans, G
Hankinson, SE
Hoffman-Bolton, J
Key, TJ
Krogh, V
Nichols, HB
Sandler, DP
Schoemaker, MJ
Sluss, PM
Sund, M
Swerdlow, AJ
Visvanathan, K
Liu, M
Zeleniuch-Jacquotte, A
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
A strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important because of the paucity of biomarkers of breast cancer risk in premenopausal women. We conducted a consortium study including ten prospective cohorts that had collected blood from premenopausal women. A nested case-control design was implemented within each cohort. A total of 2,835 invasive (80%) and in situ (20%) breast cancer cases were individually matched to controls (n = 3,122) on age at blood donation. AMH was measured using a high sensitivity enzyme-linked immunoabsorbent assay. Conditional logistic regression was applied to the aggregated dataset. There was a statistically significant trend of increasing breast cancer risk with increasing AMH concentration (ptrend across quartiles <0.0001) after adjusting for breast cancer risk factors. The odds ratio (OR) for breast cancer in the top vs. bottom quartile of AMH was 1.60 (95% CI = 1.31-1.94). Though the test for interaction was not statistically significant (pinteraction  = 0.15), the trend was statistically significant only for tumors positive for both estrogen receptor (ER) and progesterone receptor (PR): ER+/PR+: ORQ4-Q1  = 1.96, 95% CI = 1.46-2.64, ptrend <0.0001; ER+/PR-: ORQ4-Q1  = 0.82, 95% CI = 0.40-1.68, ptrend  = 0.51; ER-/PR+: ORQ4-Q1  = 3.23, 95% CI = 0.48-21.9, ptrend  = 0.26; ER-/PR-: ORQ4-Q1  = 1.15, 95% CI = 0.63-2.09, ptrend  = 0.60. The association was observed for both pre- (ORQ4-Q1 = 1.35, 95% CI = 1.05-1.73) and post-menopausal (ORQ4-Q1  = 1.61, 95% CI = 1.03-2.53) breast cancer (pinteraction  = 0.34). In this large consortium study, we confirmed that AMH is associated with breast cancer risk, with a 60% increase in risk for women in the top vs. bottom quartile of AMH.
URI
https://repository.icr.ac.uk/handle/internal/989
DOI
https://doi.org/10.1002/ijc.31249
Collections
  • Breast Cancer Research
  • Genetics and Epidemiology
Subject
Humans
Breast Neoplasms
Logistic Models
Odds Ratio
Risk Assessment
Risk Factors
Case-Control Studies
Prospective Studies
Adult
Aged
Middle Aged
Female
Anti-Mullerian Hormone
Research team
Aetiological Epidemiology
Language
eng
Date accepted
2017-12-07
License start date
2018-06
Citation
International journal of cancer, 2018, 142 (11), pp. 2215 - 2226

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.